Literature DB >> 11557760

Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance.

H Nakajima1, N Kiyokawa, Y U Katagiri, T Taguchi, T Suzuki, T Sekino, K Mimori, T Ebata, M Saito, H Nakao, T Takeda, J Fujimoto.   

Abstract

Shiga toxin (Stx) binds to the receptor glycolipid Gb3Cer on the cell surface and is responsible for hemolytic uremic syndrome. Stx has two isoforms, Stx1 and Stx2, and in clinical settings Stx2 is known to cause more severe symptoms, although the differences between the mechanisms of action of Stx1 and Stx2 are as yet unknown. In this study, the binding modes of these two isoforms to the receptor were investigated with a surface plasmon resonance analyzer to compare differences by real time receptor binding analysis. A sensor chip having a lipophilically modified dextran matrix or quasicrystalline hydrophobic layer was used to immobilize an amphipathic lipid layer that mimics the plasma membrane surface. Dose responsiveness was observed with both isoforms when either the toxin concentration or the Gb3Cer concentration was increased. In addition, this assay was shown to be specific, because neither Stx1 nor Stx2 bound to GM3, but both bound weakly to Gb4Cer. It was also shown that a number of fitting models can be used to analyze the sensorgrams obtained with different concentrations of the toxins, and the "bivalent analyte" model was found to best fit the interaction between Stxs and Gb3Cer. This shows that the interaction between Stxs and Gb3Cer in the lipid bilayer has a multivalent effect. The presence of cholesterol in the lipid bilayer significantly enhanced the binding of Stxs to Gb3Cer, although kinetics were unaffected. The association and dissociation rate constants of Stx1 were larger than those of Stx2: Stx2 binds to the receptor more slowly than Stx1 but, once bound, is difficult to dissociate. The data described herein clearly demonstrate differences between the binding properties of Stx1 and Stx2 and may facilitate understanding of the differences in clinical manifestations caused by these toxins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557760     DOI: 10.1074/jbc.M106015200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting.

Authors:  Ming-Hsin Li; Seok Ki Choi; Thommey P Thomas; Ankur Desai; Kyung-Hoon Lee; Alina Kotlyar; Mark M Banaszak Holl; James R Baker
Journal:  Eur J Med Chem       Date:  2011-11-23       Impact factor: 6.514

2.  Note: Model identification and analysis of bivalent analyte surface plasmon resonance data.

Authors:  Purushottam Babu Tiwari; Aykut Üren; Jin He; Yesim Darici; Xuewen Wang
Journal:  Rev Sci Instrum       Date:  2015-10       Impact factor: 1.523

3.  Identification of amino acids critical for the cytotoxicity of Shiga toxin 1 and 2 in Saccharomyces cerevisiae.

Authors:  Rong Di; Eric Kyu; Varsha Shete; Hemalatha Saidasan; Peter C Kahn; Nilgun E Tumer
Journal:  Toxicon       Date:  2010-12-22       Impact factor: 3.033

4.  Key role of receptor density in colloid/cell specific interaction: a quantitative biomimetic study on giant vesicles.

Authors:  M Lamblet; B Delord; L Johannes; D van Effenterre; P Bassereau
Journal:  Eur Phys J E Soft Matter       Date:  2008-05-15       Impact factor: 1.890

5.  Structural and molecular basis for hyperspecificity of RNA aptamer to human immunoglobulin G.

Authors:  Shin Miyakawa; Yusuke Nomura; Taiichi Sakamoto; Yoshiki Yamaguchi; Koichi Kato; Satoko Yamazaki; Yoshikazu Nakamura
Journal:  RNA       Date:  2008-04-25       Impact factor: 4.942

Review 6.  Glycosphingolipid functions.

Authors:  Clifford A Lingwood
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

Review 7.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

Review 8.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Interaction of the verotoxin 1B subunit with soluble aminodeoxy analogues of globotriaosyl ceramides.

Authors:  Murugesapillai Mylvaganam; Henrik C Hansen; Beth Binnington; Göran Magnusson; Per-Georg Nyholm; Clifford A Lingwood
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

10.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Authors:  Richard L Siegler; Tom G Obrig; Theodore J Pysher; Vernon L Tesh; Nathaniel D Denkers; Fletcher B Taylor
Journal:  Pediatr Nephrol       Date:  2003-01-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.